HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G/Wella

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble Prestige Beauty Fine Fragrances and Clairol will be combined with Wella and Cosmopolitan Cosmetics under a unit to be overseen by Wella CEO Heiner Gurtler, P&G announces July 14. Gurtler is appointed group president-global prestige and professional care, reporting to P&G CEO A.G. Lafley. "This structure will ensure that Wella's prestige and professional care expertise is preserved and further developed," Gurtler notes. Wella distributes fragrances under Cosmopolitan Cosmetics. According to P&G, any changes to distribution of its prestige beauty or fragrance lines have not been established, but the company recently announced plans to terminate its U.S. fragrance distribution agreement with Clarins effective Dec. 31, 2005. In addition to Gurtler's appointment, P&G names Executive VP-Wella Professional, America/Asia/Pacific Carsten Fischer to the post of President-Professional Care, and Vice-President-Global Fine Fragrances Hartwig Langer to President-Prestige Products, both reporting to Gurtler...

You may also be interested in...



Wella To Appoint New CEO Following Gurtler’s Departure

Wella's supervisory board will name a new CEO in September to succeed Heiner Gurtler, who announced June 29 that he will step down as head of the Procter & Gamble division in October. The exec will simultaneously leave his position as P&G group president, global prestige and professional care

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel